Attendees who purchased access to the 2016 Annual Meeting webcast were sent login information on May 11, 2016.

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 5 records per page: next > | last >>
pages: 1 2 3 4 5 presentations: 1 to 25 of 121
Assay Validation (Educational Session)
Exploiting the Success and Failure of Cancer Therapies: Investing Now in Accurate Biomarker Data to Improve Outcomes Later
Peter S. Nelson, M.D.
Fred Hutchinson Cancer Research Ctr., Seattle, WA
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 22, 2008 12:00 PM-2:00 PM
Assay Validation (Educational Session)
Biomarker Validation: Pre-analytic and Assay Performance
Dr. Andrew Hruszkewycz
National Cancer Institute, Rockville, MD
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 22, 2008 12:00 PM-2:00 PM
Assay Validation (Educational Session)
Accurate, Reproducible, and Quantitative Measurement of Protein Analyte Concentration(s) in Tissue Slides
David L. Rimm, M.D., Ph.D.
Yale Univ. School of Medicine, New Haven, CT
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 22, 2008 12:00 PM-2:00 PM
Assay Validation (Educational Session)
Statistical Issues in Biomarker Assay Development and Evaluation
Viswanath Devanarayan, Ph.D.
Abbott Laboratories, Parsippany NJ
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 22, 2008 12:00 PM-2:00 PM
Molecular Markers and Patient Decisions (Educational Session)
Beyond Comprehension: Challenges in Helping People Use Genetic Information Wisely
Dr. Peter A. Ubel
University of Michigan, Ann Arbor, MI
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 22, 2008 2:15 PM-4:15 PM
Molecular Markers and Patient Decisions (Educational Session)
Decision Tools: The Challenge of Integrating New Molecular Biomarkers and Classical Information
Dr. Peter M. Ravdin
University of Texas Health Science Center, San Antonio, TX
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 22, 2008 2:15 PM-4:15 PM
Molecular Markers and Patient Decisions (Educational Session)
Patient Styles of Coping with Risk Feedback
Suzanne M. Miller, Ph.D.
Fox Chase Cancer Center, Cheltenham, PA
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 22, 2008 2:15 PM-4:15 PM
Molecular Markers and Patient Decisions (Educational Session)
Panel Discussion
Panelists:
Susan Friedman, D.V.M.
FORCE, Fort Lauderdale, Florida
Daniel F. Hayes, M.D.
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
Robert McCormack, Ph.D.
Veridex, LLC, Raritan, NJ
Suzanne M. Miller, Ph.D.
Fox Chase Cancer Center, Cheltenham, PA
Jane Perlmutter, Ph.D.
Gemini Group, Naperville, IL
Dr. Peter M. Ravdin
University of Texas Health Science Center, San Antonio, TX
Dr. Steven Shak
Genomic Health, Inc., Redwood, CA
Dr. Peter A. Ubel
University of Michigan, Ann Arbor, MI
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 22, 2008 2:15 PM-4:15 PM
Molecular Marker Driven Trial Design (Educational Session)
Statistical Issues in Identifying, Validating and Using Molecular Markers in Clinical Trials
Marc E. Buyse, Sc.D.
International Drug Development Institute, Ottignies, Belgium
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 22, 2008 4:30 PM-6:30 PM
Molecular Marker Driven Trial Design (Educational Session)
Multiple Markers-the FDA Perspective
Steven I. Gutman, M.D.
Food and Drug Administration, Rockville, MD
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 22, 2008 4:30 PM-6:30 PM
Molecular Marker Driven Trial Design (Educational Session)
Molecular Marker Driven Trial Design
Donald A. Berry, Ph.D.
UT M.D. Anderson Cancer Center, Houston, TX
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 22, 2008 4:30 PM-6:30 PM
Opening Session
Welcome
Margaret Foti, Ph.D., M.D. (h.c.)
American Association for Cancer Research, Philadelphia, PA
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 22, 2008 7:30 PM-9:00 PM
Opening Session
Models of Molecular Diversity to Facilitate Marker Guided Therapy
Joe W. Gray, Ph.D.
Lawrence Berkeley National Laboratory, Berkeley, CA
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 22, 2008 7:30 PM-9:00 PM
Transformative Technology (Plenary Session)
High Content Imaging in Cancer Drug Discovery
Dr. Jonathan Yingling
Eli Lilly and Company, Indianapolis, IN
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 23, 2008 8:00 AM-10:00 AM
Transformative Technology (Plenary Session)
PET Technology for Interrogating Genome Functions and Genome Variations in Cancer Cells
Dr. Yijun Ruan
Genome Institute of Singapore, Singapore
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 23, 2008 8:00 AM-10:00 AM
Transformative Technology (Plenary Session)
Summary
David A. Tuveson, M.D., Ph.D.
CRUK Cambridge Research Institute, Cambridge, United Kingdom
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 23, 2008 8:00 AM-10:00 AM
Pharmacogenomics (Plenary Session)
Germline Pharmacogenomics as a Tool to Individualize Therapy in Breast Cancer
Dr. David A. Flockhart
Indiana University Cancer Center, Indianapolis, IN
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 23, 2008 10:45 AM-12:45 PM
Pharmacogenomics (Plenary Session)
Genome-wide Association Studies in Clinical Trials
Dr. Nancy Cox
The University of Chicago, Chicago, IL
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 23, 2008 10:45 AM-12:45 PM
Pharmacogenomics (Plenary Session)
Personalized Medicine: Advantages and Shortcomings of Genomics versus Metabonomics
Dr. Daniel W. Nebert
University of Cincinnati Medical Center
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 23, 2008 10:45 AM-12:45 PM
Pharmacogenomics (Plenary Session)
Proffered Talk (15 minutes)
Ged Brady, Ph.D.
Epistem PLC, Manchester, United Kingdom
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 23, 2008 10:45 AM-12:45 PM
Molecular Classification and Prognostic Markers (Plenary Session)
Early Detection of Colon Cancer Using Methylated Fecal DNA
Sandy Markowitz, M.D., Ph.D.
Case Western Reserve University, Cleveland, OH
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 23, 2008 4:30 PM-6:30 PM
Molecular Classification and Prognostic Markers (Plenary Session)
Src Pathway Activation Correlates with Treatment Resistance in Breast Cancer and Identifies Patient Subsets Predicted to Benefit from Src Inhibition
Christina M. Coughlin, M.D., Ph.D.
Wyeth Research, Collegeville, PA
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 23, 2008 4:30 PM-6:30 PM
Molecular Classification and Prognostic Markers (Plenary Session)
Ovarian Cancer Classification: Lessons from Morphology, Molecules and Mice
Kathleen Cho, M.D.
University of Michigan Medical School, Ann Arbor, MI
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 23, 2008 4:30 PM-6:30 PM
Molecular Classification and Prognostic Markers (Plenary Session)
Pharmacogenetics of Lung Cancer: An Integrative Epidemiologic Approach
Margaret Spitz, M.D.
UT M. D. Anderson Cancer Center, Houston, TX
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 23, 2008 4:30 PM-6:30 PM
Molecular Response Prediction Markers (Plenary Session)
Molecular Markers Predictive of Response to EGFR Inhibitors
Bruce E. Johnson, M.D.
Dana-Farber Cancer Institute, Boston, MA
from 2008 Molecular Diagnostics in Cancer Therapeutic Development conference on September 24, 2008 8:00 AM-10:15 AM
<< first | < prev page: of 5 records per page: next > | last >>
pages: 1 2 3 4 5 presentations: 1 to 25 of 121